Alex Biese

A diagnosis of anal cancer can feel overwhelming, but understanding the disease is the first step toward effective management and recovery.

Dispelling myths and misconceptions and shedding light on disparities in hospice care.

Actor Dave Coulier, best known for his role in the sitcom “Full House,” recently sat down with CURE to discuss facing cancer for the second time.

The FDA granted regular approval to treatment with Rubraca for some adult patients with previously-treated metastatic castration-resistant prostate cancer.

CURE contributor Brian Sluga discusses his new memoir, “The Shriek I Do Remember.”

The FDA has approved Enhertu and Perjeta for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

The FDA has granted breakthrough therapy designation to INCA033989 for some patients with essential thrombocythemia.

This guide features information from diagnosis to treatment of adenocarcinoma of the bladder.

For AYA breast cancer survivors, mobile health intervention was associated with improvements to general and cancer-specific quality of life.

Real-world treatment with Yescarta demonstrated durable responses and manageable safety in patients with relapsed/refractory follicular lymphoma.

CURE spoke with a Mayo Clinic expert about the current status of breast cancer vaccines.

Although great strides have been made in research for breast cancer vaccines, such a vaccine is likely years away from commercial availability.

A Mayo Clinic Expert Corrected Some Common Misconceptions Regarding Breast Cancer Vaccines

Among children receiving chemotherapy for acute lymphoblastic leukemia, 30% of their families developed catastrophic financial toxicity.

The FDA approved Breyanzi for adults with relapsed or refractory marginal zone lymphoma who received at least two prior lines of systemic therapy.

As part of her journey with stage 3 inflammatory breast cancer, Lindsey Gunter experienced chemotherapy side effects so severe that she was unable to walk.

The FDA granted traditional approval to Jaypirca for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

CURE recently sat down with an expert to discuss crucial information for patients with gastrointestinal stromal tumors, or GISTs.

Among young patients, clinical trial results have shown that Pedmark is associated with a reduction in chemotherapy-induced ear damage.

Breaking down what patients need to know about penile cancer, from diagnosis to treatment.

CURE discussed the regional anesthesia technique known as PEC I and II blocks with breast surgeon Dr. Christopher M. McGreevy.

Research is underway for an experimental treatment for patients with succinate dehydrogenase deficient gastrointestinal stromal tumors.

After more than 30 years since she was first diagnosed with a myeloproliferative neoplasm, Nona Baker is hopeful for the future thanks to current clinical trial landscape.

Immunotherapies have represented a revolution in the landscape of cancer treatment — and may have a crucial partner in the form of personalized cancer vaccines.

The FDA approved Imfinzi with chemotherapy for adults with resectable gastric or gastroesophageal junction adenocarcinoma.

From diagnosis to treatment, here is what patients need to know about squamous cell carcinoma of the bladder.

The phase 2 SANRECO study has recently completed enrollment and will evaluate divesiran, a potential therapy for patients with polycythemia vera.

Researchers identified a potential unmet need for an effective early treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

In a recent interview with CURE, Nona Baker shared insights from her blood cancer journey that began more than 30 years ago.

Nona Baker received a diagnosis of essential thrombocythemia in 1991, followed by polycythemia vera in 2004.